The successful introduction of genetically engineered human and chimeric immunoglobulin proteins has established monoclonal antibodies as a validated approach for treating malignancies. This review examines the optimal design of these agents, the lessons learned from clinical immunoconjugate development, and the promising agents in early preclinical and clinical development for the treatment of cancer.
- Alejandro D Ricart
- Anthony W Tolcher